Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C
Hepatology Research, Volume 42, No. 7, Year 2012
Notification
URL copied to clipboard!
Description
Aim: There is considerable variation in liver fibrosis stage and progression to cirrhosis among patients with chronic hepatitis B (CHB) or C (CHC). Coagulation pathway activity due to genetic variations could influence the rate of fibrosis. We investigated thrombotic risk factors and their association with the extent and progression of fibrosis in CHB or CHC patients. Methods: In total, 194 patients with CHB (n=88) or CHC (n=106) were included. Data on demographic and laboratory findings were collected. Liver biopsies were evaluated according to the Ishak classification system. Fibrosis progression rate (FPR), defined as ratio of fibrosis score to duration of infection, was determined for 131 patients. Prevalence of factor V Leiden, prothrombin G20210A, plasminogen activator inhibitor type-1 (PAI-1) 4G/5G and factor XIIIA Val34Leu mutations was evaluated. Results: Heterozygosity for factor V Leiden, prothrombin G20210A, PAI-1 4G/5G and factor XIIIA Val34Leu mutations was present in 3.1%, 2.1%, 49% and 28% of the patients, respectively. Factor XIII Val34Leu mutation was a risk for enhanced FPR (odds ratio 4.7; P=0.01). In patients with both factor XIII Val34Leu and PAI-1 4G/5G mutations the risk of an accelerated FPR was further increased (odds ratio 5.0; P=0.02). Mutations of the other thrombotic genes were not significantly associated with fibrosis stage and FPR. Conclusion: Our data show that factor XIII Val34Leu mutation alone or in combination with PAI-1 4G/5G mutation is a risk factor for an increased rate of liver fibrosis development in patients with CHB or CHC. © 2012 The Japan Society of Hepatology.
Authors & Co-Authors
Dik, Kathelijne
Netherlands, Amsterdam
Universiteit Van Amsterdam
de Bruijne, Joep
Netherlands, Amsterdam
Universiteit Van Amsterdam
Takkenberg, Robert Bart
Netherlands, Amsterdam
Universiteit Van Amsterdam
Roelofs, Joris J.T.H.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Tempelmans, Marjan J.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Dijkgraaf, Marcel G.W.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Gelderblom, Huub C.
United Kingdom, Oxford
University of Oxford
South Africa, Durban
The Nelson R. Mandela Medical School
Reésink, Hendrick W.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Meijers, Joost C.M.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Jansen, Peter L.M.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Levi, Marcel M.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Statistics
Citations: 11
Authors: 11
Affiliations: 3
Identifiers
Doi:
10.1111/j.1872-034X.2011.00963.x
ISSN:
13866346
e-ISSN:
1872034X
Research Areas
Cancer
Genetics And Genomics
Infectious Diseases
Study Design
Cross Sectional Study
Case-Control Study